HTG Molecular Diagnostics, Firalis Partner on NGS-Based RA Theranostic | GenomeWeb

NEW YORK (GenomeWeb) – HTG Molecular Diagnostics and French biotechnology firm Firalis announced yesterday that they have formed a partnership to develop a next-generation sequencing-based assay for identifying rheumatoid arthritis (RA) patients like to respond to anti-TNF-alpha therapies.

Called RABIOPRED, the assay was developed through a EU-funded project led by French personalized medicine firm Tc Land Expression and Firalis. It is based on a gene-expression panel that includes more than 2,100 microRNAs and runs on HTG's EdgeSeq platform.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.

Mar
28
Sponsored by
Illumina

This webinar describes the optimization and validation of two commercially available next-generation sequencing assays that may be used to guide personalized cancer treatment. 

Mar
30
Sponsored by
SeraCare

Our roundtable of industry experts will provide an overview of the current regulatory landscape for clinical genomics tests.

Apr
13
Sponsored by
SeraCare

In this webinar, Gregory J. Tsongalis of Dartmouth Hitchcock Medical Center will discuss how his lab developed and validated a cancer hotspot assay. 

Apr
27
Sponsored by
SeraCare

This webinar is the third in a four-part series highlighting real-world examples of how some lab directors are bringing validated next-generation sequencing-based tests to the clinic.